Abstract
Atopic dermatitis (AD) is characterized by skin barrier dysfunction, for which the abnormal stratum corneum (sc) ceramide composition serves as one of the driving factors. Here, we assess effect of dupilumab on the regulation of skin barrier function and sc ceramide composition in patients with AD. BALISTAD (NCT04447417) was an open-label trial, in which Trans-epidermal Water Loss (TEWL) was assessed via skin tape strip (STS) samples from lesional skin of 26 patients with AD treated with dupilumab and from normal skin of 26 healthy volunteers over 16 weeks.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
